<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062059</url>
  </required_header>
  <id_info>
    <org_study_id>InstiGem</org_study_id>
    <nct_id>NCT03062059</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence</brief_title>
  <official_title>The Effectiveness and Safety of Intravesical Gemcitabine Instillation During Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma: Prospective, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness and safety of intravesical
      gemcitabine instillation during operation to prevent intravesical recurrence after radical
      nephroureterectomy in upper urinary tract urothelial carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Intervention Model: Single Group Assignment

      Masking: Open Label

      Primary Outcome Measures:

      Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation
      group and control group.

      Secondary Outcome Measures:

      Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control
      group.

      Safety of intravesical 2000mg/52.6ml gemcitabine instillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. The recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>six years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group.</measure>
    <time_frame>six years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT cystography finding at one week after surgery.</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score questionnaire at one week after surgery.</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravesical 2000mg/52.6ml gemcitabine instillation</intervention_name>
    <description>Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects who will undergo nephroureterectomy due to ureter or renal pelvis
             urothelial carcinoma

          -  Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed
             as upper urinary tract urothelial carcinoma

          -  Normal bone marrow function: Hemoglobin &gt;10 g/dL, ANC &gt;1,500/mm3, platelet
             count&gt;100,000/mm3

          -  Normal bladder volume and function

          -  Normal liver function:

          -  Bilirubin ≤ 1.5 times of upper normal limit

          -  AST/ALT ≤ 1.8 times of upper normal limit

          -  Alkaline phosphatase ≤ 1.8 times of upper normal limit

          -  Subjects who voluntarily decided to participate and signed the written informed
             consent

        Exclusion Criteria:

          -  Concomitant bladder cancer

          -  Subjects who underwent any treatment due to bladder cancer within 3 years

          -  Prior hypersensitivity reaction history to gemcitabine

          -  Neurogenic bladder

          -  Subjects who underwent chemotherapy due to any cancer within 6 months

          -  Subjects who underwent neoadjuvant chemotherapy due to ureter or renal pelvis
             urothelial carcinoma

          -  Hypersensitivity to gemcitabine or component of gemcitabine

          -  In case of co-administration of gemcitabine and cisplatin in severe renal failure
             patients

          -  Moderate to severe liver dysfunction or renal dysfunction (Glomerular filtration rate
             &lt; 30 mL/min)

          -  Severe bone marrow suppression

          -  Severe infection

          -  Female who are pregnant or has a possibility of pregnancy

          -  Nursing female

          -  Interstitial pneumonia or pulmonary fibrosis which is evident on chest x-ray and
             symptomatic

          -  Subjects who are undergoing radiotherapy on chest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho Kyung Seo, M.D.</last_name>
    <phone>82-31-920-1678</phone>
    <email>seohk@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoon Seok Suh, M.D.</last_name>
    <phone>82-10-5019-9807</phone>
    <email>12754@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Kyung Seo, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jinsoo Chung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Han Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bum Sik Hong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Ho Kang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byong Chang Jeong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja Hyun Ku, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 22, 2017</lastchanged_date>
  <firstreceived_date>February 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Ho Kyung Seo</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
